The Unexpected Fertility Connection
A growing body of evidence is confirming what fertility specialists and obstetricians have been observing anecdotally for months: women taking GLP-1 receptor agonist drugs for weight management are experiencing unplanned pregnancies at rates significantly higher than expected. A new multi-center retrospective study published in the journal Fertility and Sterility has put numbers to the phenomenon, and they are striking.
The study, which analyzed health records from over 48,000 women of reproductive age taking semaglutide, tirzepatide, or Foundayo between January 2025 and March 2026, found that the incidence of unplanned pregnancy was 2.7 times higher than in a matched control group not taking GLP-1 medications.
Understanding the Mechanism
Researchers have identified several interconnected mechanisms that may explain the fertility surge among GLP-1 drug users:
- Weight loss restores ovulation — Excess body weight is a well-known cause of anovulatory cycles. Rapid weight loss can restore regular ovulation in women who were previously subfertile due to conditions like polycystic ovary syndrome (PCOS)
- Improved insulin sensitivity — GLP-1 drugs improve insulin signaling, which directly affects ovarian function and can normalize sex hormone levels
- Reduced oral contraceptive absorption — GLP-1 drugs slow gastric emptying, which may alter the absorption kinetics of oral contraceptive pills, potentially reducing their effectiveness
- Hormonal rebalancing — Weight loss-induced changes in estrogen, testosterone, and sex hormone-binding globulin (SHBG) levels can shift the hormonal environment toward greater fertility
Clinical Data Highlights
The Fertility and Sterility study revealed several notable patterns in the data:
- The highest pregnancy rates occurred between months 3 and 6 of GLP-1 therapy, corresponding to the period of most rapid weight loss
- Women with a prior diagnosis of PCOS had a 3.4-fold increase in pregnancy rates compared to the control group
- Among women using oral contraceptives as their sole contraceptive method, the failure rate was approximately 9.2%, compared to the typical 7% failure rate in the general population
- The effect was most pronounced in women who lost more than 10% of their baseline body weight
"We are essentially restoring fertility in women whose weight was acting as an unintentional contraceptive. The medical community needs to recognize this and counsel patients accordingly." — Lead study author, Fertility and Sterility
Implications for Contraception Counseling
The findings have significant implications for how physicians prescribe GLP-1 drugs to women of reproductive age. Several professional organizations are now updating their guidance to address the issue.
The American College of Obstetricians and Gynecologists (ACOG) issued a practice advisory recommending that all women of childbearing potential starting GLP-1 therapy receive comprehensive contraception counseling. The advisory specifically recommends considering non-oral contraceptive methods such as IUDs, implants, or injectable contraceptives, which are not affected by changes in gastric emptying.
The PCOS Connection
Perhaps the most dramatic fertility effects are being seen in women with PCOS, a condition affecting an estimated 6-12% of women of reproductive age. PCOS is characterized by insulin resistance, hormonal imbalances, and irregular ovulation — all of which are directly addressed by GLP-1 drug therapy.
Reproductive endocrinologists report that some women with PCOS who had been trying to conceive for years are becoming pregnant within months of starting GLP-1 therapy. While this is welcome news for those seeking fertility, it represents an unexpected pregnancy risk for women taking the drugs purely for weight management.
Drug Manufacturer Responses
Pharmaceutical companies that manufacture GLP-1 drugs have begun updating their prescribing information in response to the emerging data. Novo Nordisk has added language to the Wegovy label advising healthcare providers to discuss contraception with female patients. Eli Lilly is reportedly conducting a focused pharmacokinetic study on the interaction between Foundayo and oral contraceptives.
All major GLP-1 drug manufacturers maintain that their medications are contraindicated during pregnancy and recommend discontinuing use at least two months before a planned conception, though the exact washout period varies by drug.
What Women Should Know
Healthcare providers emphasize that women taking GLP-1 drugs should be proactive about their reproductive health planning. Key recommendations include discussing contraceptive options with a healthcare provider before starting GLP-1 therapy, considering long-acting reversible contraception if pregnancy is not desired, taking a pregnancy test if a period is missed during treatment, and not stopping GLP-1 medication abruptly without medical guidance.
The intersection of obesity treatment and fertility represents a new frontier in women's health that will require ongoing research and evolving clinical practice.
